Wall Street analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to announce earnings per share (EPS) of ($1.09) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Flexion Therapeutics’ earnings. The highest EPS estimate is ($0.99) and the lowest is ($1.19). Flexion Therapeutics reported earnings per share of ($0.78) during the same quarter last year, which indicates a negative year-over-year growth rate of 39.7%. The business is scheduled to issue its next quarterly earnings results after the market closes on Thursday, March 8th.
On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($3.84) per share for the current fiscal year, with EPS estimates ranging from ($3.95) to ($3.73). For the next fiscal year, analysts anticipate that the company will post earnings of ($4.12) per share, with EPS estimates ranging from ($4.62) to ($3.80). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Flexion Therapeutics.
Several research firms have issued reports on FLXN. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Northland Securities restated a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Friday, November 10th. Finally, Berenberg Bank began coverage on shares of Flexion Therapeutics in a research note on Thursday, February 1st. They issued a “buy” rating and a $42.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $99.11.
Flexion Therapeutics (NASDAQ FLXN) traded down $0.20 during midday trading on Friday, reaching $25.16. 605,478 shares of the company’s stock traded hands, compared to its average volume of 747,113. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25. The firm has a market capitalization of $944.53, a P/E ratio of -7.15 and a beta of 0.91.
TRADEMARK VIOLATION WARNING: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3231643/flexion-therapeutics-inc-flxn-expected-to-post-earnings-of-1-09-per-share.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.